ARIA Related Analyst PT Change
-
Jefferies Cuts PT on ARIAD Pharma (ARIA) Due to Iclusig Safety Issues, Maintains Buy
-
Oppenheimer Downgrades ARIAD Pharmaceuticals (ARIA) to Perform
-
Jefferies Boosts Price Target on Ariad Pharmaceuticals (ARIA) as Drugs Show Promise
-
Brean Murray Carret & Co Increases Price Target on ARIAD (ARIA) to $35
-
Jefferies Raises Target on ARIAD Pharmaceuticals (ARIA) Following Q4 Results
Back to ARIA Stock Lookup
